再鼎医药Zai Lab Limited (ZLAB) 2017年20-F年度报告「NASDAQ」.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 20-F (Mark One)REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934 ORANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended Decembe

2、r 31,2017 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file numbe

3、r 001-38205 ZAI LAB LIMITED(Exact name of Registrant as specified in its charter)N/A(Translation of Registrants name into English)Cayman Islands(Jurisdiction of incorporation or organization)4560 Jinke RoadBldg.1,Fourth FloorPudongShanghai,China 201210(Address of principal executive offices)Samantha

4、 DuChief Executive OfficerZai Lab Limited4560 Jinke RoadBldg.1,Fourth FloorPudongShanghai,China 201210Telephone:+86 21 6163 2588(Name,telephone,email and/or facsimile number and address of Company contact person)Securities registered or to be registered pursuant to Section 12(b)of the Act:Title of e

5、ach class Name of each exchange on which registeredAmerican depositary shares,each representing oneordinary share,par value$0.00006 per share Nasdaq Global Market Securities registered or to be registered pursuant to Section 12(g)of the Act:None(Title of Class)Securities for which there is a reporti

6、ng obligation pursuant to Section 15(d)of the Act:None(Title of Class)Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the Annual Report:50,555,903 ordinary shares were issued and outstanding as of December 3